Minerva Neurosciences Inc. (NERV) posted a GAAP net loss of $125.4 million for the quarter ended March 31 2026, translating to a loss of $2.86 per share. The loss represents a sharp increase from the $3.8 million loss reported for the same period in 2025, underscoring the impact of a one‑time charge on the company’s bottom line.
The headline loss is largely attributable to a $109.4 million non‑cash expense related to warrant liability changes and exercise losses. When adjusted for non‑GAAP items, the company’s net loss shrank to $7.3 million, or $0.17 per share, a figure that is only slightly higher than the $3.5 million ($0.46 per share) loss recorded in Q1 2025. The disparity illustrates how the warrant liability charge inflates the GAAP loss without affecting cash flows.
Operating expenses rose sharply in the quarter. General & Administrative costs climbed to $11.4 million from $2.5 million in Q1 2025, driven by $8.0 million in non‑cash stock compensation and a $6.6 million one‑time option‑modification charge. Research & Development spending increased to $5.3 million from $1.4 million, reflecting the company’s investment in the global Phase 3 MIN‑101C19 trial for roluperidone, its lead candidate for negative symptoms of schizophrenia.
Cash on hand at March 31 2026 stood at $78.2 million, down from $82.4 million at the end of 2025. The company estimates that this balance will support at least a 12‑month runway under current burn rates, providing a buffer as the Phase 3 trial progresses toward its first topline data set in the second half of 2027.
Minerva’s focus remains on advancing roluperidone, with the Phase 3 trial expected to generate critical efficacy data. Management expressed confidence that the current cash position will sustain operations through the trial’s enrollment and data‑collection phases, and no new financing has been announced to extend the runway further.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.